Phase II trial of AE 37 in patients with prostate cancer

Trial Profile

Phase II trial of AE 37 in patients with prostate cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2015

At a glance

  • Drugs AE 37 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2015 According to a Generex Biotechnology media release, Antigen Express has entered into a Memorandum of Understanding with CompanDX to conduct this study. CompanDX has established a subsidiary, TumourVac, for the administration of the Phase II AE37 prostate cancer study.
    • 03 Jan 2012 Generex intends to move ahead with this trial more rapidly than anticipated, according to a company media release.
    • 06 Oct 2011 Antigen Express is continuing with plans for this trial, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top